Author

Andrew Rankin

Observed name: Andrew N. Rankin

Institution: Foundation Medicine (United States)

Observed institutions: Mayo Clinic, The University of Texas MD Anderson Cancer Center, Foundation Medicine (United States)

OpenAlex ID: A5019168443

Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer

2017 · Jeremy C. Jones, Lindsay A. Renfro, et al. · Journal of Clinical Oncology · 339

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site

2015 · Jeffrey S. Ross, Kai Wang, et al. · JAMA Oncology · 244

Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer

2016 · Andrew Rankin, Samuel J. Klempner, et al. · The Oncologist · 40

Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers

2020 · Andrew Rankin, Adrienne Johnson, et al. · The Oncologist · 33

Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant

2017 · Christine A. Parachoniak, Andrew Rankin, et al. · Molecular Case Studies · 24

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response

2019 · Andge Valiakhmetova, Sergey Gorelyshev, et al. · The Oncologist · 17

Genomic Landscape of Adult and Pediatric BCR-ABL1-Like B-Lymphoblastic Leukemia Using Parallel DNA and RNA Sequencing

2018 · Eric A. Severson, Jo-Anne Vergilio, et al. · The Oncologist · 8

Comprehensive genomic profiling of advanced colorectal carcinoma in the course of clinical care to identify KRAS insertions not detected by focused molecular testing.

2016 · Andrew Rankin, Alexa Betzig Schrock, et al. · Journal of Clinical Oncology

Works count: 8

Citation count: 705

H-index: 7

I10-index: 6